FDA Seeks Injunction Against ‘Anticancer’ Drug Maker

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 3
Volume 9
Issue 3

ROCKVILLE, Md-The FDA has accused Lane Labs-USA, Inc., of Allendale, NJ, with illegally promoting three products as treatments for cancer and other diseases, and is seeking a permanent federal court injunction against the marketing of the products: BeneFin, produced from shark cartilage; SkinAnswer, a glycoalkaloid skin cream; and MGN-3, a rice-bran extract.

ROCKVILLE, Md—The FDA has accused Lane Labs-USA, Inc., of Allendale, NJ, with illegally promoting three products as treatments for cancer and other diseases, and is seeking a permanent federal court injunction against the marketing of the products: BeneFin, produced from shark cartilage; SkinAnswer, a glycoalkaloid skin cream; and MGN-3, a rice-bran extract.

The FDA noted that BeneFin is being studied as a cancer therapy under an investigational new drug application and it can be distributed for clinical trials. The legal action does not affect shark cartilage products that are lawfully marketed as dietary supplements.

Related Videos
Video 4 - "Frontline Treatment for EGFR-Mutated Lung Cancer"
Video 3 - "NGS Testing Challenges and Considerations in NSCLC"
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
Related Content